Citations

Clear

15 citation(s) found for "Holland, Thomas L".

Age, Multidomain Lifestyle Intervention, and White Matter Integrity
Maillard, P, Vemuri, Prashanthi, Harvey, Danielle J., Harrison, Theresa M., Reddy, Ashritha L., Oh, Hwamee, Salloway, Stephen, Holland, Thomas M., Rw, Whitmer, Espeland, M A, Baker, Laura D. , Landau, Susan M., DeCarli, Charles, Harvey, Danielle , Harvey, Danielle J , Maillard, Pauline , Vemuri, Prashanthi , Harrison, Theresa M. , Oh, Hwamee , Salloway, Stephen , Mahinrad, Simin , Holland, Thomas Monroe , Whitmer, Rachel A. , Landau, Susan , DeCarli, Charles

Mayo Clinic

JAMA Network Open | July 13, 2026 | Volume: 9 | Issue: 7 | Pages: e2620353

10.1001/jamanetworkopen.2026.20353 | PMID 42438415 Get It

Importance Multidomain lifestyle interventions slow cognitive decline in at-risk older adults, but effects on cerebrovascular injury and whether any effect differs by age or across magnetic resonance imaging (MRI) markers remain unclear. Objectives To test whether a structured multidomain lifestyle intervention, vs a self-guided program, alters trajectories of cerebrovascular MRI markers and whether baseline diffusion MRI estimates subsequent vascular injury. Design, Setting, and Participants POINTER Imaging was a prespecified secondary imaging analysis of the US POINTER (US Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk) randomized clinical trial conducted at multiple US sites. Starting August 1, 2020, and continuing until March 1, 2023, all newly enrolled US POINTER trial participants who met criteria, including being 60 to 79 years of age and at increased risk for cognitive decline, were given the opportunity to enroll in POINTER Imaging. Annual MRIs were performed at baseline and up to 2 follow-up visits at 12 and 24 months. The imaging study ended May 14, 2025. Interventions Structured multidomain lifestyle arm (supervised exercise, dietary counseling, cognitive and social engagement, and health coaching) vs self-guided educational arm. Main Outcomes and Measures Primary outcomes were cerebrovascular MRI markers of global white matter free water (FW), fractional anisotropy (FA), peak width of skeletonized mean diffusivity (PSMD), analysis along the perivascular space (ALPS) index, white matter hyperintensity (WMH) volume, and incident cerebral microbleeds (CMBs). Age-group analyses (<70 vs ≥70 years) were prespecified. Linear mixed-effects models tested time, intervention arm, age group, and interactions for continuous outcomes; logistic regression evaluated incident CMBs. All analyses were adjusted for sex, hypertension, diabetes, and smoking and were conducted for the evaluable population. Data were analyzed September 5 to December 11, 2025. Results For 959 participants included in the analysis, the mean (SD) age was 68 (5) years, and 594 (61.9%) were female. A significant time × arm × age group interaction was observed for FW (β = 0.050; SE = 0.018; P = .006). In participants younger than 70 years, the structured intervention, compared with the self-guided intervention, attenuated the FW increase over time (β = −0.031; SE = 0.012; P = .009); no intervention arm difference was observed in participants aged 70 years or older (β = 0.019; SE = 0.014; P = .18). No intervention-related interactions were detected (eg, time × intervention arm interaction) for WMH (β = 0.002; SE = 0.016; P = .90), FA (β = 0.016; SE = 0.016; P = .30), PSMD (β = −0.011; SE = 0.021; P = .60), or ALPS (β = 0.006; SE = 0.021; P = .79). Overall, greater odds of incident CMBs were associated with higher baseline FW (odds ratio, 1.63 [95% CI, 1.24-2.14]; P < .001) and PSMD (odds ratio, 1.40 [95% CI, 1.08-1.81]; P < .001). Greater WMH progression was associated with higher baseline FW (β = 0.014; SE = 0.006; P = .02) and lower baseline FA (β = −0.018; SE = 0.006; P = .004). Conclusions and Relevance In this secondary imaging analysis of a randomized clinical trial, FW was the cerebrovascular MRI marker most responsive to lifestyle intervention in adults 60 to 70 years of age, showing attenuated small-vessel disease–related injury. Findings suggested greater microvascular benefit when intensive lifestyle intervention is implemented earlier in late life. Trial Registration ClinicalTrials.gov Identifier: NCT03688126
Fast Antimicrobial Susceptibility Testing for Gram-Negative Bacteremia
Banerjee, Ritu, Komarow, Lauren , Li, Yixuan, Mau, Donald, Geres, Holly, Greenwood-Quaintance, Kerryl, Adler, Amos , Baliga, S, Chrysos, George , Zarkotou, Olympia , Paul, Mical, Regueiro, Dolores Sousa, Chambers, Henry, Fowler, Vance G., Patel, Robin, Group, Antibacterial Resistance Leadership, Chambers, Henry F. , Cross, Heather, Harris, Anthony D. , Duin, David van, Boucher, Helen W., Huntley, Clayton C., Raterman, Erica L., Samuel, Tamika, Moon, Kyung, Holland, Thomas L., Lodise, Thomas, Shelburne, Samuel A. , Cosgrove, Sara E., Lautenbach, Ebbing , Mehigan, Maureen, Doernberg, Sarah B. , Perdue, Sam, Singh, Tara A. , Wickward, Cathy, Souto, David A., Waller, Jason, Evans, Scott R , Banerjee, Ritu , Dodd, Andrew, Geres, Holly, Greenwood‐Quaintance, Kerryl E. , Baliga, Shrikala , Chowers, Michal , Paul, Mical, Pournaras, Spyros , Fowler, Vance G. , Patel, Robin , Evans, Scott , Hamasaki, Toshimitsu , Pettigrew, Melinda M. , Hanson, Kimberly E. , Doi, Yohei , Holland, Thomas L. , Cosgrove, Sara E. , Paterson, David L.

Mayo Clinic

JAMA | April 18, 2026 | Volume: 335 | Issue: 20 | Pages: 1762

10.1001/jama.2026.5487 | PMID 41999287 Get It

Importance Novel blood culture diagnostics provide rapid antimicrobial susceptibility testing (AST) results for bacteria causing bloodstream infections (BSIs) but have unclear clinical impact. Objective To evaluate clinical outcomes of blood culture testing using a rapid AST method compared with standard AST in patients with BSIs caused by gram-negative bacilli in regions with high prevalence of antimicrobial resistance. Design, Setting, and Participants Open-label randomized clinical trial that enrolled participants from December 2023 to May 2025 (final follow-up, June 18, 2025) at 7 medical centers in Greece (n = 2), India (n = 1), Israel (n = 3), and Spain (n = 1). Hospitalized patients (adults and children) with BSIs caused by gram-negative bacilli were eligible. Statistical analysis was conducted from August 2025 to January 2026. Intervention Patients were randomized to undergo blood culture evaluation using rapid, phenotypic AST directly from positive blood cultures plus standard susceptibility testing (n = 413) vs standard susceptibility testing alone (n = 437). Local antimicrobial stewardship teams reviewed all patients and provided treatment recommendations. Main Outcomes and Measures The primary outcome was a desirability of outcome ranking (DOOR) at day 30, with 3 categories (alive without deleterious events, alive with deleterious events, and death). The difference between rapid and standard testing was summarized as the probability that the DOOR outcomes were more desirable in the rapid testing group. Superiority was concluded if the lower limit of the 95% CI exceeded 50%. Secondary outcomes included 30-day mortality, length of hospitalization, intensive care unit admission, acquisition of hospital-acquired infections, time to effective antibiotic therapy within 3 days, and time to antibiotic escalation or deescalation within 3 days. Results Of the 899 patients randomized, 850 were included in the primary outcome analysis (median [IQR] age, 72 [21] years; 43% female). The probability that DOOR outcomes were more favorable in the rapid testing group was 48.8% (95% CI, 45.3%-52.4%). Median time to effective antibiotic therapy was not different between the groups in the as-randomized population. Median time to antibiotic escalation or deescalation was faster in the rapid testing group by 14 hours (95% CI, 6-22) in the as-randomized population. There were no differences between the groups in other secondary outcomes. In the prespecified subgroup with carbapenem-resistant infections, median time to effective therapy was 9.5 hours in the rapid testing group vs 28 hours in the standard testing group (difference, −18 hours [95% CI, −42 to 6]). Conclusions and Relevance Among patients with gram-negative bacilli BSIs, rapid blood culture AST was not superior to standard testing by DOOR. When considered with other efficacy and safety outcomes, these findings may help inform the use of rapid susceptibility testing in clinical practice. Trial Registration ClinicalTrials.gov Identifier: NCT06174649
Escherichia coli ST131 Drives Carbapenem Use for E. coli Bloodstream Infections
Mackow, Natalie , Shao, Wanying, Ge, Lizhao , Komarow, Lauren, Jiang, Jianping , Boutzoukas, Angelique , Chen, Liang , Herc, Erica, Doi, Yohei, Arias, Cesar A, Jacob, J, Satlin, Michael J. , Huskins, W Charles, Dhar, Sorabh, Shelburne, Samuel A, Hill, Carol, Sadler, Jacob M., Hill, Bravada M, Greenwood-Quaintance, Kerryl E, Schmidt-Malan, Suzannah M., Patel, Robin, Fowler, Vance G, Tamma, Pranita D, Kreiswirth, Barry N, Group, for the Antibacterial Resistance Leadership, Chambers, Chip, Evans, Scott, Hamasaki, Toshi, Cross, Heather, Harris, Anthony, Pettigrew, Melinda M. , Duin, David van, Boucher, Helen , Dixon, Dennis O., Ghazaryan, Varduhi , Zou, Lanling, Raterman, Erica, Samuel, Tamika, Moon, Kyung, Hanson, Kim, Holland, Thomas, Lodise, Tom, Shelburne, Sam, Banerjee, Ritu, Cosgrove, Sara, Paterson, David, Lautenbach, Ebbing , Mehigan, Maureen, Doernberg, Sarah, Doi, Yohei , Chen, Liang , Boutzoukas, Angelique E , Jiang, Jianping , Doi, Yohei , Albin, Owen , Saade, Elie , Miller, Loren G , Jacob, Jesse T , Satlin, Michael J , Krsak, Martin , Huskins, W Charles , Shelburne, Samuel A , Hill, Carol , Alby, Kevin , Sadler, Jacob M , Hill, Bravada M , Patel, Robin , Fowler, Vance G. , Tamma, Pranita D , van Duin, David , Pettigrew, M M , Evans, Scott R , Ge, Lizhao , Komarow, Lauren , Garcia‐Diaz, Julia , Herc, Erica , Arias, César A. , Albin, Owen , Saade, Elie , Jacob, Jesse T. , Kršák, Martin , Huskins, W. Charles , Dhar, Sorabh , Shelburne, Samuel A. , Hill, Carol , Alby, Kevin , Greenwood‐Quaintance, Kerryl E. , Patel, Robin , Tamma, Pranita D. , Kreiswirth, Barry N , Evans, Scott, Raterman, Erica L., Samuel, Tamika, Banerjee, Ritu , Cosgrove, Sara E. , Paterson, David L. , Mehigan, Maureen

Mayo Clinic

Clinical Infectious Diseases | March 4, 2026 | Volume: 83 | Issue: 1 | Pages: e27-e37

10.1093/cid/ciag160 | PMID 41795867 Get It

Abstract Background Ceftriaxone-resistant Escherichia coli infections are increasingly common, partially because of the emergence of E. coli sequence type 131 (ST131), including its subclade C2/H30Rx, which produce extended-spectrum β-lactamases. Methods A prospective cohort including 14 US sites, which enrolled monomicrobial ceftriaxone-resistant and susceptible E. coli bloodstream infection (BSI) cases in a 1:1 ratio, was used to compare ST131 versus non-ST131 E. coli BSI, with specific attention to E. coli ST131 C2/H30Rx. Desirability of outcome ranking was determined at 30 days after infection onset. Results This analysis included 282 patients with E. coli BSI; 43% (121/282) were E. coli ST131 and 23% (66/282) belonged to the C2/H30Rx subclade. Resistance to ceftriaxone was present in 79% (96/121) ST131, 86% (57/66) E. coli ST131 C2/H30Rx, and 27% (43/161) E. coli non-ST131. Compared to patients with non-ST131 E. coli BSI, patients with ST131 BSI were older (median 70 years, [Q1 62, Q3 76] years vs 65 years, [51, 74]; P = .005) and more often admitted from long-term care facilities (21/121 [17%] vs 7/161 [4%], P < .001). Overall and empiric carbapenem use was more frequent in the treatment of patients with ST131 BSI compared with non-ST131 BSI (overall 89/121 [74%] vs 50/161 [31%]; empiric: 58/121 [48%] vs 31/161 [19%], P < .001). Desirability of outcome ranking outcomes were similar between groups. Conclusions Most ceftriaxone-resistant E. coli from US patients with E. coli BSI belong to ST131, particularly E. coli ST131 C2/H30Rx, serving as an important driver of carbapenem use.
Association of neighborhood deprivation with Alzheimer's Disease pathologies, gray matter volume, white matter hyperintensities and cognition by sex, race or ethnicity and APOE4 status in Non‐demented Older Adults
Aguilar, Pablo Analuisa, Lockhart, Sam, Masdeu, Joseph C. , Snyder, Heather M. , Landau, Susan M., Arenaza‐Urquijo, Eider M, Holland, Thomas Monroe , Masdeu, Joseph C , Neumann, Lycia Tramujas Vasconcellos , Baker, Laura D. , Landau, Susan, Arenaza‐Urquijo, Eider M.

Mayo Clinic

Alzheimer's & Dementia | December 23, 2025 | Volume: 21 | Issue: S6 | Pages: No page available

10.1002/alz70860_105535 Get It

Abstract Background Neighborhood socio‐economic conditions may increase Alzheimer's disease (AD) risk through amyloid, tau, atrophy or vascular pathways, potentially varying by genetic risk, race or ethnicity and sex. We examined associations between Area Deprivation Index (ADI) and cognition, AD pathology, gray matter (GM) and white matter hyperintensities (WMH) volume in cognitively unimpaired older adults by race or ethnicity, sex and APOE4 status. Method We included 1896 non‐demented older adults from US POINTER study with available cognitive evaluations, ADI level – a census–based neighborhood disadvantage metric (categorized as low, moderate and high) and a subsample with neuroimaging data ( N = 806). Linear/logistic regressions were used to assess interactions of ADI with sex, race or ethnicity, and APOE4 on (1) the Preclinical Alzheimer's Cognitive Composite, (PACC‐5), (2) MRI‐derived GM volume meta‐ROI (entorhinal, fusiform, parahippocampal, mid‐temporal, inferior temporal), (3) WMH and (4) AD pathology (amyloid and tau PET), adjusted by age, sex and intracranial volume when appropriate. Result African American participants ( p <0.001) and females ( p <0.001) were more likely to live in deprived areas. African American participants had significantly lower PACC‐5 ( p <0.001) and GM volume ( p <0.001), “Other or multiple races” participants showed significantly higher amyloid burden ( p = 0.001), and White participants higher WMH ( p = 0.013). Females showed higher PACC‐5 scores ( p <0.001), while APOE4 carriers showed lower PACC‐5 ( p = 0.042) and higher amyloid burden ( p <0.001) (Table 1). Race and ADI interacted on PACC‐5 ( p = 0.043) and showed a borderline interaction on Tau ( p = 0.079), with higher ADI linked to lower PACC‐5 in White, Hispanic, and “Other or Multiple Races” and higher Tau in Hispanic. Further, there was a borderline ADI*APOE4 status interaction on WMH ( p = 0.059) and a significant ADI*APOE4 interaction on amyloid ( p = 0.001), where APOE4 carriers in deprived areas showed higher WMH and lower amyloid burden (Figure 1). No significant ADI*sex interactions were observed. Conclusion Neighborhood disadvantage was more commonly observed in African American participants, but interaction with cognition was primarily seen in other racial/ethnic groups. APOE4 carriers showed increased amyloid burden, but those from more disadvantaged neighborhoods exhibited a higher vascular component alongside lower amyloid‐driven pathology. These results may indicate varying effects of social disadvantages across groups or sample bias.
Association of neighborhood social and built environment with physical activity in U.S. POINTER
Aguilar, Pablo, Lockhart, Sam, Masdeu, Joseph C. , Garcia‐Aymerich, Judith, Nieuwenhuijsen, Mark, Snyder, Heather M. , Landau, Susan M., Arenaza‐Urquijo, Eider M, Aguilar, Pablo Analuisa, Holland, Thomas Monroe , Masdeu, Joseph C , Neumann, Lycia Tramujas Vasconcellos , Valentín, Antònia , Petricola, Sami , García‐Aymerich, Judith , Nieuwenhuijsen, Mark J , Baker, Laura D. , Landau, Susan, Arenaza‐Urquijo, Eider M.

Mayo Clinic

Alzheimer's & Dementia | December 23, 2025 | Volume: 21 | Issue: S6 | Pages: No page available

10.1002/alz70860_105496 Get It

Abstract Background Neighborhood social and built environment characteristics may promote physical activity, a modifiable factor for dementia risk, which may in turn promote cognitive and brain health. We explored the associations of the U.S. National Walkability Index ‐ a nationwide geographic data resource that ranks block groups according to their relative walkability – with cognitive function, gray matter (GM) and white matter hyperintensities (WMH), neighborhood disadvantage, sedentary behavior and frequency of physical activity in cognitively unimpaired older adults at increased Alzheimer's disease (AD) risk. Method We included baseline data from 1398 older adults (68.3 ± 5.17 years, 68.3% females, 30.5% APOE4 carriers) from the U.S. POINTER trial. Walkability was classified as: least, below average, above average and most walkable. Neighborhood disadvantage (low, moderate and high) was assessed using Area Deprivation Index (ADI) ( N = 1384). Physical inactivity was assessed using the Sedentary Behavior Questionnaire (SBQ, hours sitting/week, N = 1106), and physical activity was measured with a composite score from the Community Health Activities Model Program for Seniors (CHAMPS) questionnaire. Linear and logistic regressions examined associations between walkability and (1) physical activity and sedentary behavior; and (2) cognition assessed with the Preclinical Alzheimer's Cognitive Composite (PACC‐5), GM volume and WMHs, Additionally, associations between neighborhood disadvantage and physical activity and sedentary behavior were explored. Models were adjusted for age, sex, race, APOE4 and total intracranial volume. Result More deprived areas were generally less walkable (β = ‐0.008, p < 0.001) (Figure 1). Higher walkability (Above average: β = 0.192, p = 0.011 and most walkable: β = 0.183, p = 0.032) was associated with higher PACC‐5 (Figure 2A) scores but not with more preserved GM or lower WMH. Walkability scores were not associated with physical activity and sedentary measurements, while greater neighborhood disadvantage was linked to sedentary behavior (β = 0.126, p < 0.001) (Figure 2B). Conclusion These results suggest that physical inactivity in more deprived areas is associated with neighborhood socioeconomic disadvantages rather than built environment. Additionally, walkability scores were not associated with any measure of physical activity or brain health, suggesting the need to further investigate other health effects of neighborhood disadvantage and walkability.
Sociodemographic associations with AD biomarkers in POINTER, UBRAIN, and ADNI
Aguilar, Pablo Analuisa, Colceriu, Carmen M, López, A., Franquesa‐Mullerat, María , Zsadanyi, Sara E, Farias, Sarah, Lockhart, Sam, Masdeu, Joseph C. , Fortea, Juan M., Lleó, Alberto, Snyder, Heather M. , Sánchez‐Valle, Raquel, Landau, Susan M., Arenaza‐Urquijo, Eider M, Colceriu, Carmen M, Zsadanyi, Sara Erzsebet , Pérez‐Millan, Agnès , Farias, Sarah Tomaszewski , Tort‐Merino, Adrià , Holland, Thomas Monroe , Masdeu, Joseph C , Neumann, Lycia Tramujas Vasconcellos , Valentín, Antònia , Petricola, Sami , Fortea, Juan , Lleó, Alberto , Baker, Laura D. , Sánchez‐Valle, Raquel , Bejanin, Alexandre , Landau, Susan, Arenaza‐Urquijo, Eider M.

Mayo Clinic

Alzheimer's & Dementia | December 23, 2025 | Volume: 21 | Issue: S6 | Pages: No page available

10.1002/alz70860_101102 Get It

Abstract Background In aging and dementia research, the relationships between modifiable risk factors and biomarkers often vary across cohorts. We aim to evaluate the consistency and generalizability of the association between the area deprivation index (ADI) ‐ an indicator of socioeconomic/resource disadvantage within a specific area ‐ and cognition and Alzheimer's disease (AD) biomarkers across three distinct research cohorts, two from the U.S. (U.S. POINTER Imaging, ADNI) and one from Spain (UBRAIN). Method We included a total of 3091 participants without dementia, 1879 from U.S. POINTER Imaging, 282 from ADNI and 930 from UBRAIN (Table 1). The ADI was calculated using validated indices from the US and Spain, with neighborhood deprivation ranked as Low, Moderate, and High in the US, and Low and High in Spain. Outcomes of interest included (1) the preclinical Alzheimer's cognitive composite (PACC‐5), (2) MRI‐derived gray matter volumes in AD‐vulnerable regions and (3) PET or CSF‐derived amyloid status (+/‐). We ran logistic regression models with ADI level as predictor adjusted by sex, age, and APOE4 and considered education and race or ethnicity (only US cohorts) in our analyses. Result Participants in more deprived areas had lower education across cohorts and were more likely to be female (U.S. POINTER) and African American (U.S. POINTER and ADNI, Table 1). Independent of age, sex and APOE4 status, higher ADI was associated with lower PACC in U.S. POINTER (Moderate: β=‐0.165, p <0.001; High β=‐0.412, p <0.001) and UBRAIN (ADI: High β=‐0.096, p = 0.022) but not in ADNI (Figure 1). After controlling for education, this association remained significant in U.S. POINTER (Moderate: β=‐0.166, p = 0.002; High: β=‐0.248, p = 0.007) but not in UBRAIN (β=‐0.021, p = 0.66). In U.S. POINTER, there was a trend towards an association of higher ADI with lower GM volume in AD‐vulnerable regions (β=‐0.126, p = 0.089) that was not observed in ADNI or UBRAIN (Figure 2). No associations between ADI and amyloid status were found across cohorts. Conclusion We observed differing associations in neighborhood deprivation and cognition across US cohorts, as well as between the US and Spain cohorts. Country‐specific factors and sample representativeness must be considered when investigating the pathophysiologic mechanisms underlying social determinants and disparities in AD.
External Validation of the 2023 Duke–International Society for Cardiovascular Infectious Diseases Diagnostic Criteria for Infective Endocarditis
Vaart, Thomas W. van der , Durack, David T., Karchmer, Adolf W. , Moreillon, Philippe, Selton‐Suty, Christine , Fowler, Vance G. , Meer, Jan T. M. van der, van der Vaart, Thomas W , Rasmussen, Magnus , Selton-Suty, Christine , Bossuyt, Patrick M. , Baddour, Larry M. , Bayer, Arnold S. , Durante‐Mangoni, Emanuele , Holland, Thomas L , Miró, José María , Fowler, Vance G.

Mayo Clinic

Clinical Infectious Diseases | February 8, 2024 | Volume: 78 | Issue: 4 | Pages: 922-929

10.1093/cid/ciae033 | PMID 38330166 Get It

Abstract Background The 2023 Duke–International Society of Cardiovascular Infectious Diseases (ISCVID) criteria for infective endocarditis (IE) were introduced to improve classification of IE for research and clinical purposes. External validation studies are required. Methods We studied consecutive patients with suspected IE referred to the IE team of Amsterdam University Medical Center (from October 2016 to March 2021). An international expert panel independently reviewed case summaries and assigned a final diagnosis of “IE” or “not IE,” which served as the reference standard, to which the “definite” Duke-ISCVID classifications were compared. We also evaluated accuracy when excluding cardiac surgical and pathologic data (“clinical” criteria). Finally, we compared the 2023 Duke-ISCVID with the 2000 modified Duke criteria and the 2015 and 2023 European Society of Cardiology (ESC) criteria. Results A total of 595 consecutive patients with suspected IE were included: 399 (67%) were adjudicated as having IE; 111 (19%) had prosthetic valve IE, and 48 (8%) had a cardiac implantable electronic device IE. The 2023 Duke-ISCVID criteria were more sensitive than either the modified Duke or 2015 ESC criteria (84.2% vs 74.9% and 80%, respectively; P &lt; .001) without significant loss of specificity. The 2023 Duke-ISCVID criteria were similarly sensitive but more specific than the 2023 ESC criteria (94% vs 82%; P &lt; .001). The same pattern was seen for the clinical criteria (excluding surgical/pathologic results). New modifications in the 2023 Duke-ISCVID criteria related to “major microbiological” and “imaging” criteria had the most impact. Conclusions The 2023 Duke-ISCVID criteria represent a significant advance in the diagnostic classification of patients with suspected IE.
963. External Validation of the 2023 Duke - International Society for Cardiovascular Infectious Diseases (ISCVID) Diagnostic Criteria for Infective Endocarditis (IE)
Durack, David T., Karchmer, Adolf W. , Miró, José M., Moreillon, Philippe, Fowler, Vance G. , Meer, Jan T. M. van der, Vaart, Thomas W. van der , Bossuyt, Patrick M. , Baddour, Larry M. , Bayer, Arnold S. , Durante‐Mangoni, Emanuele , Holland, Thomas L , Rasmussen, Magnus , Selton‐Suty, Christine , Fowler, Vance G.

Mayo Clinic

Open Forum Infectious Diseases | November 27, 2023 | Volume: 10 | Issue: Supplement_2 | Pages: No page available

10.1093/ofid/ofad500.024 Get It

Abstract Background The 2023 Duke-ISCVID criteria for IE were recently introduced to improve classification of IE for research and clinical purposes (Table 1). We compared the diagnostic accuracy of the new criteria with the 2000 modified Duke criteria, the 2015 European Society of Cardiology (ESC) criteria and a clinically adjudicated reference standard by a panel of international experts on IE.Table 1:Overview of changes in criteria from 2000 modified Duke to 2023 Duke-ISCVIDAdapted from: Fowler et al, Clinical Infectious Diseases, 2023 Methods The study population consisted of consecutively enrolled patients suspected to have IE and discussed by the IE team of the Amsterdam University Medical Center (AMC) between October 2016 and March 2021. A panel of international experts on IE assigned a final diagnosis, which served as the reference standard. We compared the definite classification of the 2023 Duke-ISCVID criteria against this reference standard. We also evaluated accuracy of the new criteria, excluding data obtained from cardiac surgery and pathology (“Clinical Criteria”). Lastly, we quantified the added value of the proposed changes to the criteria, and compared the 2023 Duke-ISCVID to previous criteria using the McNemar test. We performed sensitivity analyses in patients who underwent cardiac surgery and patients who underwent TEE. Results 595 patients with suspected IE were included, of whom 399 (67%) were adjudicated as having IE. 111 patients (19%) had prosthetic valve IE, 48 (8%) had cardiac implantable electronic device IE. The 2023 Duke-ISCVID criteria were more sensitive than the modified Duke or ESC criteria (84.2 vs 74.9 vs 80%,respectively, p &lt; 0.001 for ISCVID vs ESC criteria) without significant loss of specificity (Table 2). After excluding cardiac surgery/pathology results, the 2023 Duke-ISCVID Clinical Criteria also had significantly better sensitivity than the modified Duke and ESC criteria, again without losing specificity. The changes in the 'major microbiological' and 'imaging' criteria had the most impact (Figure 1). Findings were robust in sensitivity analyses (Table 3). When classifying ‘definite’ and ‘possible’ IE as a positive test, the 2023 Duke-ISCVID criteria had 99% sensitivity compared to the reference standard, but specificity decreased to 21%.Table 2:Diagnostic accuracy of modified Duke, ESC and Duke-ISCVID criteria Sensitivity and specificity are against the reference standard (adjudication panel). The Clinical Criteria classification is the Duke-ISCVID classification when results from surgery or post-mortem studies are not used to determine classification.Table 3:Sensitivity analyses of accuracy of Duke-ISCVID criteria In the Definite + Possible analysis, patients with possible IE according to the Duke-ISCVID criteria were also considered as having IE. All comparisons are against the reference standard (adjudication panel). Conclusion In this cohort, the 2023 Duke-ISCVID criteria represent a significant advance in the diagnostic classification of patients suspected of IE. Added value of new Duke-ISCVID criteria compared to modified Duke criteria Each point (red square for sensitivity, blue circle for specificity) provides the diagnostic accuracy measure for the 2000 modified Duke Criteria with addition of a specific change from the Duke-ISCVID criteria. The horizontal bars represent the 95% confidence interval for the point estimate. The top points represent the modified Duke criteria without addition, the bottom points are the complete Duke-ISCVID criteria. Disclosures Larry M. Baddour, MD, Boston Scientific: Advisor/Consultant|Roivant Sciences: Advisor/Consultant Arnold S. Bayer, MD, Akagera Medicines: Grant/Research Support|ContraFect Corporation: Grant/Research Support Emanuele Durante Mangoni, MD,, PhD, Advanz pharma: Advisor/Consultant|Advanz pharma: Grant/Research Support|Advanz pharma: Honoraria|Angelini: Grant/Research Support|Angelini: Honoraria|Genentech: Advisor/Consultant|Genentech: Board Member|Genentech: Honoraria|Infectopharm: Grant/Research Support|Menarini: Board Member|Menarini: Honoraria|Pfizer: Advisor/Consultant|Pfizer: Board Member|Pfizer: Grant/Research Support|Pfizer: Honoraria|Roche: Advisor/Consultant|Roche: Board Member|Roche: Honoraria Thomas L. Holland, MD, Aridis: Advisor/Consultant|Basilea Pharmaceutica: Advisor/Consultant|Karius: Advisor/Consultant|Lysovant: Advisor/Consultant Adolf W. Karchmer, MD, Karius: Grant/Research Support|Up To Date: Honoraria Vance G. Fowler, MD, MHS, Amphliphi Biosciences, Integrated Biotherapeutics; C3J, Armata, Valanbio; Akagera, Aridis, Roche, Astra Zeneca: Advisor/Consultant|Genentech, Regeneron, Deep Blue, Basilea, Janssen;: Grant/Research Support|Infectious Diseases Society of America: Honoraria|MedImmune, Allergan, Pfizer, Advanced Liquid Logics, Theravance, Novartis, Merck; Medical Biosurfaces; Locus; Affinergy; Contrafect; Karius;: Grant/Research Support|Novartis, Debiopharm, Genentech, Achaogen, Affinium, Medicines Co., MedImmune, Bayer, Basilea, Affinergy, Janssen, Contrafect, Regeneron, Destiny,: Advisor/Consultant|Sepsis diagnostic: Patent pending|UpToDate: Royalties|Valanbio and ArcBio: Stock Options
The Future Ain’t What It Used to Be…Out With the Old…In With the Better: Antibacterial Resistance Leadership Group Innovations
Patel, Robin , Hamasaki, Toshimitsu , Howard‐Anderson, Jessica , Kinamon, Tori, King, H. A. , Cross, H. R. , Chambers, Henry F. , Fowler, Vance G. , Boucher, Helen W., Group, for the Antibacterial Resistance Leadership, Schooley, Robert T. , Banerjee, Ritu , Souli, Maria , Sund, Zoë, Evans, Beth , Booth, Grant, Estes, Leslie, Greenwood‐Quaintance, Kerryl E. , Parmar, Krupa , Schwager, Nyssa, Wickward, Cathy, Geres, Holly, Dai, Weixiao , He, Yijie, Doernberg, Sarah B. , Satlin, Michael J. , Rouphael, Nadine , Baum, Keri, Raza, Praneeta , Komarow, Lauren , Hopkins, D. E., Zhang, Shanshan , Patel, Robin , Evans, Scott R , Evans, Scott , King, Heather A, Collyar, Deborah , Cross, Heather R, Fowler, Vance G. , Group, for the Antibacterial Resistance Leadership, Tamma, Pranita D. , Evans, Beth, Cunningham, Scott A. , Tillekeratne, L. Gayani , Dodd, Andrew, Hopkins, Deborah, Li, Yixuan , Tsalik, Ephraim L. , Holland, Thomas L

Mayo Clinic

Clinical Infectious Diseases | October 16, 2023 | Volume: 77 | Issue: Supplement_4 | Pages: S321-S330

10.1093/cid/ciad538 | PMID 37843122 Get It

Abstract Clinical research networks conduct important studies that would not otherwise be performed by other entities. In the case of the Antibacterial Resistance Leadership Group (ARLG), such studies include diagnostic studies using master protocols, controlled phage intervention trials, and studies that evaluate treatment strategies or dynamic interventions, such as sequences of empiric and definitive therapies. However, the value of a clinical research network lies not only in the results from these important studies but in the creation of new approaches derived from collaborative thinking, carefully examining and defining the most important research questions for clinical practice, recognizing and addressing common but suboptimal approaches, and anticipating that the standard approaches of today may be insufficient for tomorrow. This results in the development and implementation of new methodologies and tools for the design, conduct, analyses, and reporting of research studies. These new methodologies directly impact the studies conducted within the network and have a broad and long-lasting impact on the field, enhancing the scientific value and efficiency of generations of research studies. This article describes innovations from the ARLG in diagnostic studies, observational studies, and clinical trials evaluating interventions for the prevention and treatment of antibiotic-resistant bacterial infections.
The Antibacterial Resistance Leadership Group: Scientific Advancements and Future Directions
Chambers, Henry F. , Cross, H. R. , Souli, Maria , Patel, Robin , Fowler, Vance G. , Group, for the Antibacterial Resistance Leadership, Deckard, Nancie , Schuler, Carl, Bunn, Ivra, Zaharoff, Smitha, Sharma, Shrabani, Wickward, Cathy, Waller, Jason, Wilson, Holly, Baum, Keri, Komarow, Lauren , Evans, Beth , Hopkins, D. E., Ge, Lizhao , Giri, Abhigya, Dai, Weixiao , Diao, Guoqing , Fidler, Tamara, Shao, Wanying, Schwager, Nyssa, Mau, Donald, Satlin, Michael J. , Schooley, Robert T. , Sund, Zoë, Booth, Grant, Estes, Leslie, Greenwood‐Quaintance, Kerryl E. , Parmar, Krupa , Doernberg, Sarah B. , Raza, Praneeta , Zeng, Lijuan , Banerjee, Ritu , Abbenante, Erin, Mocka, Elizabeth, King, H. A. , Kinamon, Tori, Boucher, Helen W., Geres, Holly, He, Yijie, Mehigan, Maureen, Ghazaryan, Varduhi , Raterman, Erica L., Samuel, Tamika, Lee, Marina S. , Fowler, Vance G. , Patel, Robin , Evans, Scott R , Cross, Heather R, Evans, Scott , Group, for the Antibacterial Resistance Leadership, Lodise, Thomas P. , Schuler, Carl, Holland, Thomas L , Turner, Nicholas , Wilson, Holly, van Duin, David , Wang, Minggui, Evans, Beth, Hopkins, Deborah, Bonomo, Robert A. , Li, Yixuan , Tamma, Pranita D. , Hamasaki, Toshimitsu , Cunningham, Scott A. , Dodd, Andrew, Tsalik, Ephraim L. , Tillekeratne, L. Gayani , King, Heather, Kinamon, Tori, Howard‐Anderson, Jessica , Nayak, Seema , Samuel, Tamika

Mayo Clinic

Clinical Infectious Diseases | October 16, 2023 | Volume: 77 | Issue: Supplement_4 | Pages: S279-S287

10.1093/cid/ciad475 | PMID 37843121 Get It

AbstractIn this overview, we describe important contributions from the Antibacterial Resistance Leadership Group (ARLG) to patient care, clinical trials design, and mentorship while outlining future priorities. The ARLG research agenda is focused on 3 key areas: gram-positive infections, gram-negative infections, and diagnostics. The ARLG has developed an innovative approach to clinical trials design, the desirability of outcome ranking (DOOR), which uses an ordinal measure of global outcome to assess both benefits and harms. DOOR was initially applied to observational studies to determine optimal dosing of vancomycin for methicillin-resistant Staphylcococcus aureus bacteremia and the efficacy of ceftazidime-avibactam versus colistin for the treatment of carbapenem-resistant Enterobacterales infection. DOOR is being successfully applied to the analysis of interventional trials and, in collaboration with the US Food and Drug Administration (FDA), for use in registrational trials. In the area of diagnostics, the ARLG developed Master Protocol for Evaluating Multiple Infection Diagnostics (MASTERMIND), an innovative design that allows simultaneous testing of multiple diagnostic platforms in a single study. This approach will be used to compare molecular assays for the identification of fluoroquinolone-resistant Neisseria gonorrhoeae (MASTER GC) and to compare rapid diagnostic tests for bloodstream infections. The ARLG has initiated a first-in-kind randomized, double-blind, placebo-controlled trial in participants with cystic fibrosis who are chronically colonized with Pseudomonas aeruginosa to assess the pharmacokinetics and antimicrobial activity of bacteriophage therapy. Finally, an engaged and highly trained workforce is critical for continued and future success against antimicrobial drug resistance. Thus, the ARLG has developed a robust mentoring program targeted to each stage of research training to attract and retain investigators in the field of antimicrobial resistance research.